Sign in
Taking people in United StatesPhase 3

Tests mirikizumab in children with Crohn's disease

Tests mirikizumab, compared with another treatment, in children with Crohn's disease.

Key facts

Who runs it
Eli Lilly and Company
Where
Atlanta, Boston, Burlington, Dayton, Fort Worth, Hartford, Indianapolis, Los Angeles, Morristown, New York, Philadelphia, and Seattle, United StatesSee the 15 sitesAlso in 15 other countries, 70 sites
Registry title
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Status
Recruiting
Phase
Phase 3
People taking part
90 people, planned
Started
13 Mar 2024
Expected to end
Apr 2028
Type of study
Interventional, 3 groups
Treatments tested
  • Mirikizumab
Record updated
7 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teenagers with moderately to severely active Crohn's disease. They must have had an inadequate response or intolerance to at least one Crohn's medicine.

Age
2 Years to 17 Years
Sex
All sexes can join.
Disease stage
Crohn's disease or fistulizing Crohn's disease with active colitis, ileitis, or ileocolitis. Disease must be moderately to severely active (PCDAI score ≥30). Endoscopy must show active disease (SES-CD score ≥6, or ≥4 for isolated ileal disease) within 1 month of starting the study intervention at Week 0.
Earlier treatment
Must have a documented history of inadequate response, loss of response or intolerance to at least one medicine for Crohn's disease. This may be an immunomodulator, oral or IV corticosteroid, a biologic therapy or a JAK inhibitor.

Main reasons for not taking part

  • Complications of Crohn's disease such as symptomatic strictures or stenosis, short gut syndrome, or other problems likely to need surgery
  • An abscess
  • Any bowel resection within 26 weeks
  • Any other surgery inside the abdomen within 12 weeks of baseline

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants must have a diagnosis of CD or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria
  • Participants have moderately to severely active CD (as defined by a baseline PCDAI score ≥30)
  • Participants must have endoscopy with evidence of active CD defined as SES-CD score ≥6 (or ≥4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
  • Participants must have a documented history of inadequate response, loss of response or intolerance to at least one medication used to treat CD, which may include immunomodulators, oral or IV corticosteroids, a biologic therapy or a JAK inhibitor

Who cannot take part

  • Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline
  • Participants must not have complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestations that might be anticipated to require surgery
  • Participants must not have an abscess

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 17 years old?

Where in United States

Also in 15 other countries, 70 sites

  • Children's Center for Digestive Health Care, LLCAtlanta, United StatesContact: Jeffery Lewis (principal investigator)Taking people
  • Emory UniversityAtlanta, United StatesContact: subra kugathasan (principal investigator)Taking people
  • Boston Children's HospitalBoston, United StatesContact: Athos Bousvaros (principal investigator)Not yet recruiting
  • University of Vermont Medical CenterBurlington, United StatesContact: Jillian Sullivan (principal investigator)Taking people
  • Childrens Medical CenterDayton, United StatesContact: Shehzad Saeed (principal investigator)Taking people
  • Cook Children's Medical CenterFort Worth, United StatesContact: Clifton Huang (principal investigator)Taking people
  • Connecticut Children's Medical CenterHartford, United StatesContact: Jeffrey Hyams (principal investigator)Taking people
  • Riley Childrens HospitalIndianapolis, United StatesContact: Steven Steiner (principal investigator)Taking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: David Ziring (principal investigator)Not yet recruiting
  • Atlantic Children's Health--Pediatric GastroenterologyMorristown, United StatesContact: Oren Koslowe (principal investigator)Not yet recruiting
  • Columbia University Medical Center New York PresbyterianNew York, United StatesContact: Joseph Picoraro (principal investigator)Taking people
  • Icahn School of Medicine at Mount SinaiNew York, United StatesContact: David Dunkin (principal investigator)Taking people
  • Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC)New York, United StatesContact: Aliza Solomon (principal investigator)Taking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Arthur Kastl (principal investigator)Taking people
  • Seattle Children's HospitalSeattle, United StatesContact: Ghassan Wahbeh (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.

Read full original descriptionShow less

Study periods for the intervention-specific appendix (ISA) will be as follows:

* A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period up to 16 weeks.

The study will last about 74 weeks and may include up to 19 visits.

The 3 groups in the trial

  • Mirikizumab Dose 1Treatment being tested

    Mirikizumab administered intravenously (IV) or subcutaneously (SC) in participants that weigh greater than (\>) 40 kilograms (kg).

    Treatment: Mirikizumab

  • Mirikizumab Dose 2Treatment being tested

    Mirikizumab administered IV or SC in participants that weigh \>20 kg to less than or equal to (≤) 40 kg. Dosing is based on assessments of the participant's weight and appropriate weight class.

    Treatment: Mirikizumab

  • Mirikizumab Dose 3Treatment being tested

    Mirikizumab administered IV or SC in participants that weigh greater than or equal to (≥) 9 kg to less than or equal to ≤20 kg. Dosing is based on assessments of the participant's weight and appropriate weight class.

    Treatment: Mirikizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease
Plain-language title
Tests mirikizumab in children with Crohn's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT05509777, who can take part
Record updated
7 October 2026